Oriol Busquets

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3052746/publications.pdf

Version: 2024-02-01

33	784	566801 15	525886 27
papers	citations	h-index	g-index

54	54	54	1392
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. Nutritional Neuroscience, 2022, 25, 2627-2637.	1.5	1
2	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. Molecular Medicine, 2022, 28, 48.	1.9	2
3	c-Jun N-Terminal Kinases in Alzheimerâ€™s Disease: A Possible Target for the Modulation of the Earliest Alterations. Journal of Alzheimer's Disease, 2021, 82, S127-S139.	1.2	7
4	Pharmacological Strategies to Improve Dendritic Spines in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, S91-S107.	1.2	13
5	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimerâ€™s disease in metabolically stressed APPswe/PS1dE9 mice. Cell and Bioscience, 2021, 11, 141.	2.1	7
6	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. International Journal of Molecular Sciences, 2020, 21, 255.	1.8	18
7	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Molecular Neurobiology, 2020, 57, 1814-1827.	1.9	51
8	Involvement of JNK1 in Neuronal Polarization During Brain Development. Cells, 2020, 9, 1897.	1.8	8
9	The preclinical discovery and development of opicapone for the treatment of Parkinsonâ€™s disease. Expert Opinion on Drug Discovery, 2020, 15, 993-1003.	2.5	5
10	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. Current Pharmaceutical Design, 2020, 26, 1286-1299.	0.9	12
11	Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimerâ€™s Disease: Co-Factor Role of Apolipoprotein E É›4. Journal of Alzheimer's Disease Reports, 2020, 4, 479-493.	1.2	7
12	JNK isoforms control mammal adult hippocampal neurogenesis. Mexican Journal of Medical Research ICSA, 2020, 8, 5-12.	0.2	1
13	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimerâ€™s Dementia. Frontiers in Aging Neuroscience, 2019, 11, 236.	1.7	40
14	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. Molecular Neurobiology, 2019, 56, 5856-5865.	1.9	20
15	A metabolic perspective of late onset Alzheimerâ€™s disease. Pharmacological Research, 2019, 145, 104255.	3.1	19
16	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. Biomedicine and Pharmacotherapy, 2019, 113, 108661.	2.5	52
17	Role of brain câ€Jun Nâ€terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a highâ€fat diet preâ€clinical model. Journal of Neurochemistry, 2019, 149, 255-268.	2.1	6
18	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. Journal of Molecular Medicine, 2019, 97, 1723-1733.	1.7	10

#	Article	IF	Citations
19	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2019, 28, 93-97.	1.9	5
20	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. Frontiers in Aging Neuroscience, 2019, 11, 344.	1.7	35
21	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. Neural Regeneration Research, 2019, 14, 1721.	1.6	2
22	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7327-7339.	1.9	24
23	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. Journal of Alzheimer's Disease, 2018, 62, 1223-1240.	1.2	150
24	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 4885-4895.	1.9	21
25	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. Neuropharmacology, 2018, 131, 440-452.	2.0	28
26	The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimerâ€™s Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet. Journal of Alzheimer's Disease, 2018, 66, 1175-1191.	1.2	10
27	The Implication of the Brain Insulin Receptor in Late Onset Alzheimerâ€™s Disease Dementia. Pharmaceuticals, 2018, 11, 11.	1.7	45
28	Experimental Models for Aging and their Potential for Novel Drug Discovery. Current Neuropharmacology, 2018, 16, 1466-1483.	1.4	35
29	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-32.	0.0	0
30	Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways. Redox Biology, 2017, 13, 345-352.	3.9	36
31	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. Pharmacological Reports, 2017, 69, 409-418.	1.5	15
32	Long-term exposition to a high fat diet favors the appearance of Î²-amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimerâ€™s disease. Mechanisms of Ageing and Development, 2017, 162, 38-45.	2.2	79
33	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. Frontiers in Bioscience - Landmark, 2017, 22, 795-814.	3.0	19